Your browser doesn't support javascript.
loading
Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis.
Tsiogkas, Sotirios G; Grammatikopoulou, Maria G; Kontouli, Katerina-Maria; Minopoulou, Ioanna; Goulis, Dimitrios D; Zafiriou, Efterpi; Bogdanos, Dimitrios P; Patsatsi, Aikaterini.
Afiliación
  • Tsiogkas SG; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
  • Grammatikopoulou MG; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
  • Kontouli KM; Laboratory of Hygiene and Epidemiology, Medical School, University of Thessaly, Larissa, Greece.
  • Minopoulou I; Department of Primary Education, School of Education University of Ioannina, Ioannina, Greece.
  • Goulis DD; Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Zafiriou E; Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Bogdanos DP; Department of Dermatology, University of Thessaly, Larissa, Greece.
  • Patsatsi A; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Expert Rev Clin Immunol ; 19(12): 1485-1498, 2023.
Article en En | MEDLINE | ID: mdl-37842734
BACKGROUND: Palmoplantar psoriasis (PP) represents a localized type of disease. While controversy over its' classification exists, a hyperkeratotic type, a pustular type and palmoplantar pustulosis (PPP) have been recognized. PP management is regularly supported by biologic agents. Our study aimed to review and synthesize available data regarding the efficacy of approved biologics for PP and PPP. RESEARCH DESIGN AND METHODS: A literature search was conducted in PubMed, CENTRAL, Scopus, and ClinicalTrilas.gov. Utilizing random-effects inverse-variance frequentist network meta-analyses (NMAs), we ranked interventions. The proportion of participants with cleared skin was the primary outcome. Fifty and 75% improvement in palmoplantar psoriasis area severity index (PPASI) were also explored (PPASI50, PPASI75). RESULTS: In total, 15 randomized controlled trials (RCTs) exploring the efficacy of on-label adalimumab, bimekizumab, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, and ustekinumab were included. Data for PP were synthesized. Every biologic agent examined, except from infliximab, outperformed placebo. On-label secukinumab exhibited the highest probability of inducing complete resolution. Ixekizumab and infliximab ranked best on inducing PPASI50 and PPASI75. Our review supports that guselkumab is effective for PPP. CONCLUSIONS: Secukinumab, ixekizumab and infliximab are effective for PP. Research is warranted to produce evidence about the efficacy of biologics in PP and PPP.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Productos Biológicos Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Expert Rev Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Productos Biológicos Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Expert Rev Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Reino Unido